Efficacy and tolerability of the specific cyclooxygenase-2 inhibitor DFP compared with naproxen sodium in patients with postoperative dental pain

Clinical Therapeutics

Volumn 21, Issue 8, 1999, Pages 1301-1312

  Gottesdiener, Keith ^a   Mehlisch, Donald R ^b   Huntington, Martha ^a   Yuan, Wei Ying ^a   Brown, Polly ^b   Gertz, Barry ^a   Mills, Stacey ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Premier Research   (United States)

Author keywords

Analgesia; COX 2; Cyclooxygenase 2 inhibitor; Dental pain

Indexed keywords

3 (2 PROPYLOXY) (4 METHYL SULFOPHENYL) (5,5 DIMETHYL) FURANONE; ANALGESIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; HYDROCODONE BITARTRATE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENTISTRY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PAIN ASSESSMENT; POSTOPERATIVE PAIN; RANDOMIZED CONTROLLED TRIAL; TOOTH EXTRACTION; TOOTH PAIN; TREATMENT OUTCOME;

EID: 0032842284     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80031-9     Document Type: Article

References (23)

1. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA. 1992;89:7384-7388.
2. Holtzman MJ, Turk J, Shornick LP. Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. J Biol Chem. 1992;267:21438-21445.
3. DeWitt D, Smith WL. Yes, but do they get headaches? Cell. 1995;83:345-348.
4. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxidase synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem. 1993;268:6610-6614.
5. Mitchel JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA. 1994;90:11693-11697.
6. O'Neill GP, Mancini JA, Kargman S, et al. Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: Inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxycicosatetraenoic acid. Mol Pharmacol. 1994;45:245-254.
7. Lee SH, Soyoola E, Chanmugam P, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem. 1992;267:25934-25938.
8. 2. Exp Cell Res. 1993;206:58-62.
9. Yamagata K, Andreasson KI, Kaufman WE, et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids. Neuron. 1993;11:371-386.
10. Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. J Clin Invest. 1994;93:1095-1101.
11. Pritchard KA, O'Banion MK, Miano JM, et al. Induction of cyclooxygenase-2 in rat vascular smooth muscle cell in vitro and in vivo. J Biol Chem. 1994;269:8504-8509.
12. Ehrich E, Mehlisch DR, Perkins S, et al. Efficacy of MK-966, a highly selective inhibitor of COX-2, in the treatment of postoperative dental pain. Arthritis Rheum. 1996;39(Suppl 9):581. Abstract.
13. Ehrich E, Schnitzer T, McIlwain H, et al. MK-966, a highly selective COX-2 inhibitor, is effective in the treatment of osteoarthritis in a 6-week pilot study. Osteoarthritis Cartilage. 1997;5(Suppl A):A161. Abstract.
14. Ehrich E, Schnitzer T, Kivitz A, et al. MK-966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee and hip in a 6-week placebo controlled study. Arthritis Rheum. 1997;40(Suppl):A330. Abstract.
15. Mehlisch DR, Hubbard RC, Isakson P, et al. Analgesic efficacy and plasma levels of a highly selective inhibitor of COX-2 (SC-58635) in patients with post-surgical dental pain. Poster presented at: Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; March 1997; San Diego, California.
16. LeBlanc Y, Brideau C, Chan C, et al. A new class of potent, orally active and selective COX-2 inhibitors-structure activity relationship. Poster presented at: Third World Congress on Inflammation; November 16-20, 1997; Tokyo, Japan.
17. Data on file. Rahway, NJ: Merck & Co., Inc; 1997.
18. Tukey JW, Ciminera JL, Heyse JF. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics. 1985;41:295-301.
19. Quan H, Capizzi TP. Adjusted trend test for a multicenter clinical trial. Proceedings of the Biopharmaceutical Section of the American Statistical Association. 1996:197-202.
20. Hosmer DW, Lemeshov S. Applied Logistic Regression. New York: John Wiley & Sons; 1989.
21. Cox DR. Regression models and life tables. J Royal Stat Soc B. 1972;34:187-220.
22. Morrison B, Christensen S, Yuan W, et al. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial. Clin Ther. 1999;21:943-953.
23. Cooper SA. Single-dose analgesic studies: The upside and downside of assay sensitivities. In: Max M, Portenoy R, Laska E, eds. Advances in Pain and Research Therapy. Vol. 18. New York: Raven Press; 1991:117-124.